Chemerin-9, Mouse是一种源于趋化素的九肽，保留了趋化素诱导原代小胶质细胞趋化性的激动活性。
Cas No.:686324-96-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Chemerin-9, Mouse is a chemerin-derived nonapeptide that retains the agonistic activity of chemerin that induces the chemotaxis of primary microglia [1]. Chemerin-9 can inhibit the formation of foam cells in macrophages induced by oxidized low-density lipoprotein (oxLDL), and prevent atherosclerosis by reducing the number of macrophages and smooth muscle cells within the plaque [2]. Chemerin-9 has been widely used to stimulate the sympathetic nerve and increase the systemic blood pressure in animal models[3].
In vitro, Chemerin-9 (100nM) treatment for 6 hours inhibited cholesterol efflux in THP-1 cells and upregulated the expression of low-density lipoprotein receptor (LDLR) [4]. Treatment with 100ng/ml Chemerin-9 for 24 hours significantly stimulated the migration activity of rat cardiac fibroblasts and promoted the phosphorylation of Akt and ERK in the cells[5].
In vivo, Chemerin-9 treatment via subcutaneous injection at a dose of 60µg/kg, every other day for 8 weeks, significantly improved Aβ deposition and cognitive impairment in APP/PS1 mice, while reducing the pro-inflammatory activity of microglia[6]. Daily intraperitoneal injection of Chemerin-9 (4µg dissolved in 200µl PBS) was administered for 42 days, which significantly increased the chemokine levels in the serum of mice with pancreatogenic diabetes mellitus (PDM) as well as the mRNA expression levels of GLUT2 and PDX1, and alleviated the glucose intolerance and insulin resistance in the mice[7].
References:
[1] Lei Z L, Lu Y Q, Bai X, et al. Chemerin-9 peptide enhances memory and ameliorates Aβ1–42-induced object memory impairment in mice[J]. Biological and Pharmaceutical Bulletin, 2020, 43(2): 272-283.
[2] Sato K, Yoshizawa H, Seki T, et al. Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis[J]. Clinical science, 2019, 133(16): 1779-1796.
[3] Yamamoto A, Matsumoto K, Hori K, et al. Acute intracerebroventricular injection of chemerin-9 increases systemic blood pressure through activating sympathetic nerves via CMKLR1 in brain[J]. Pflügers Archiv-European Journal of Physiology, 2020, 472(6): 673-681.
[4] Tan L, Wang N, Galema‐Boers A M H, et al. Statins, but not proprotein convertase subtilisin‐kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low‐density lipoprotein receptor upregulation[J]. MedComm, 2024, 5(9): e681.
[5] Yamamoto A, Sagara A, Otani K, et al. Chemerin-9 stimulates migration in rat cardiac fibroblasts in vitro[J]. European Journal of Pharmacology, 2021, 912: 174566.
[6] Zhang J, Zhang Y, Liu L, et al. Chemerin-9 is neuroprotective in APP/PS1 transgenic mice by inhibiting NLRP3 inflammasome and promoting microglial clearance of Aβ[J]. Journal of Neuroinflammation, 2025, 22(1): 5.
[7] Tu J, Yang Y, Zhang J, et al. Regulatory effect of chemerin and therapeutic efficacy of chemerin‑9 in pancreatogenic diabetes mellitus[J]. Molecular medicine reports, 2020, 21(3): 981-988.
Chemerin-9, Mouse是一种源于趋化素的九肽，保留了趋化素诱导原代小胶质细胞趋化性的激动活性[1]。Chemerin-9可抑制氧化低密度脂蛋白(oxLDL)诱导的巨噬细胞泡沫细胞形成，并通过减少斑块内巨噬细胞和平滑肌细胞数量来预防动脉粥样硬化[2]。Chemerin-9已被广泛用于刺激动物模型的交感神经并升高全身血压[3]。
在体外，使用100nM的Chemerin-9处理THP-1细胞6小时，抑制了细胞内的胆固醇外流，并上调了低密度脂蛋白受体(LDLR)的表达[4]。使用100ng/ml的Chemerin-9处理大鼠心脏成纤维细胞 24 小时，显著刺激了细胞的迁移活性，并促进了细胞内Akt和ERK的磷酸化[5]。
在体内，每隔一天皮下注射60µg/kg剂量的Chemerin-9，持续8周，显著改善了APP/PS1小鼠的Aβ沉积和认知障碍，同时降低了小胶质细胞的促炎活性[6]。每日腹腔注射Chemerin-9（4µg溶于200µl的PBS），连续42天，显著增加了胰源性糖尿病(PDM)小鼠血清中的趋化因子水平以及GLUT2和 PDX1的mRNA表达水平，并减轻了小鼠的葡萄糖耐受不良和胰岛素抵抗[7]。
| Cell experiment [1]: | |
Cell lines | Rat cardiac fibroblasts |
Preparation Method | Rat cardiac fibroblasts were cultured at 37°C and 5% CO2 in RPMI-1640 medium supplemented with 0.5% fetal bovine serum (FBS). Cells were cultured to confluency in a 6-well dish. The wounds were made by scratching the cell surface using a 10μl pipette tip. Culture media (DMEM containing 0.5% FBS) were changed, and three crossing areas were photographed by a phase-contrast microscope connected to a camera. After Chemerin-9 (100ng/ml) was added for 24h (37°C; 5% CO2), the three areas were photographed again. |
Reaction Conditions | 100ng/ml; 24h |
Applications | Chemerin-9 treatment stimulated the migration of rat cardiac fibroblasts. |
| Animal experiment [2]: | |
Animal models | APP/PS1 mice |
Preparation Method | APP/PS1 mice were accommodated within a controlled environment that was free of specific pathogens, with an ambient temperature range of 20-25°C and a light cycle of 12h on and 12h off. Chemerin-9 was dissolved in sterile PBS. Mice were treated intraperitoneally with Chemerin-9 (60µg/kg) every other day for eight weeks consecutively. The effects of Chemerin-9 on the cognitive deficits of APP/PS1 mice were evaluated using Y-maze and Morris water maze tests. |
Dosage form | 60µg/kg; every other day for 8 weeks; i.p. |
Applications | Chemerin-9 treatment ameliorated the cognitive impairment of the APP/PS1 mice. |
References: | |
| Cas No. | 686324-96-9 | SDF | |
| Canonical SMILES | O=C(N[C@@H](CC(C)C)C(N1[C@@H](CCC1)C(NCC(N[C@@H](CCC(N)=O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H](C)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](CO)C(O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC4=CC=CC=C4)N | ||
| 分子式 | C51H68N10O12 | 分子量 | 1013.16 |
| 溶解度 | 储存条件 | Store at -20°C | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 987 μL | 4.9351 mL | 9.8701 mL |
| 5 mM | 197.4 μL | 987 μL | 1.974 mL |
| 10 mM | 98.7 μL | 493.5 μL | 987 μL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet